Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keppra I.V. Formulation Is “Approvable” In U.S., Gains Positive EMEA Opinion

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised labeling for antiepileptic, manufacturing information requested by FDA already submitted, firm says.

You may also be interested in...



FDA OKs Intravenous Form Of UCB’s Keppra

UCB will launch the antiepileptic “soon,” though no specific date has been announced.

FDA OKs Intravenous Form Of UCB’s Keppra

UCB will launch the antiepileptic “soon,” though no specific date has been announced.

Keppra Pediatric Epilepsy Claim Clears FDA Under Priority Review

Indication provides for add-on treatment of children ages four years and up with partial onset epileptic seizures. Firm expects sales force expansion to be completed by year-end.

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel